COSCIENS Biopharma Inc
TSX:CSCI

Watchlist Manager
COSCIENS Biopharma Inc Logo
COSCIENS Biopharma Inc
TSX:CSCI
Watchlist
Price: 2.86 CAD -1.38%
Market Cap: 9.3m CAD

COSCIENS Biopharma Inc
Current Portion of Long-Term Debt

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

COSCIENS Biopharma Inc
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
COSCIENS Biopharma Inc
TSX:CSCI
Current Portion of Long-Term Debt
$212k
CAGR 3-Years
28%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
Current Portion of Long-Term Debt
$3.6m
CAGR 3-Years
96%
CAGR 5-Years
-1%
CAGR 10-Years
-5%
Repare Therapeutics Inc
NASDAQ:RPTX
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Current Portion of Long-Term Debt
$16.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Spectral Medical Inc
TSX:EDT
Current Portion of Long-Term Debt
CA$16.2m
CAGR 3-Years
445%
CAGR 5-Years
189%
CAGR 10-Years
N/A
No Stocks Found

COSCIENS Biopharma Inc
Glance View

Market Cap
9.1m CAD
Industry
Biotechnology

COSCIENS Biopharma Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario. COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The firm is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

CSCI Intrinsic Value
HIDDEN
Show

See Also

What is COSCIENS Biopharma Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
212k USD

Based on the financial report for Sep 30, 2025, COSCIENS Biopharma Inc's Current Portion of Long-Term Debt amounts to 212k USD.

What is COSCIENS Biopharma Inc's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
16%

Over the last year, the Current Portion of Long-Term Debt growth was -48%. The average annual Current Portion of Long-Term Debt growth rates for COSCIENS Biopharma Inc have been 28% over the past three years , 16% over the past five years .

Back to Top